-
admin
Posts
Abata Therapeutics Appoints Joanne Beck, Ph.D., as Chief Technical Officer
Dr. Beck’s extensive experience in CMC and product development will be instrumental as Abata enters clinical development this year WATERTOWN, Mass., Sept. 16, 2024 (GLOBE...
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ — Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through...
PhytoHealth Corporation announced a new clinical study results published at 2024 ESMO Congress: PG2 plus preoperative chemoradiotherapy improves survival in patients with locally advanced esophageal cancer
TAIPEI and BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ — A groundbreaking study conducted by PhytoHealth Corporation, a leading provider of botanical medicine, has revealed that combining...
China Automotive Systems Announces Annual Meeting on September 24, 2024
CAAS announces the conference call and webcast information for the Annual Meeting of Stockholders to be held on Tuesday, September 24, 2024 at 9:00 AM...
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an...
Halal Route Application – Eat, Travel around Thailand, Safe and Sound Halal Style
BANGKOK, Sept. 16, 2024 /PRNewswire/ — The Halal Science Center, Chulalongkorn University has developed Halal Route, an application that lists restaurants, lodging, mosques, prayer directions, and...
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 and anti-CTLA-4 or had primary...
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Media Release COPENHAGEN, Denmark; September 15, 2024 Treatment with rinatabart sesutecan (Rina-S) showed encouraging response rate in heavily pretreated patients with ovarian cancer in dose...
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Trial investigating Cabometyx® (cabozantinib) in combination with atezolizumab demonstrated a positive trend towards improvement for one of the primary endpoints of overall survival, but did...
World’s 1st Flashlight Experience Store Kicks Off in Las Vegas
LAS VEGAS, Sept. 15, 2024 /PRNewswire/ — Olight, a brand committed to becoming a global leader in mid-to-high-end flashlights, opened the world’s first flashlight experience store at Fashion...